Embla Medical Hf S/Adr (OSSUY) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Embla Medical Hf.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.071 -- 00:00:05.615 At this time, I would like to welcome everyone to this EMBLA Medical Q2 2026 00:00:05.615 -- 00:00:09.117 conference call. Today's call is being recorded. 00:00:09.117 -- 00:00:12.840 If you have any objections, please disconnect at this time. 00:00:12.840 -- 00:00:16.783 All participants will be on listen only mode throughout the presentation, and afterwards, 00:00:16.783 -- 00:00:18.264 there'll be a question and answer session. 00:00:18.264 -- 00:00:23.427 I would now like to introduce President and CEO Sveinn Solvason and CFO 00:00:23.427 -- 00:00:27.649 Arna Sveinsdottir. Sveinn, over to you. 00:00:27.930 -- 00:00:29.771 Thank you very much. 00:00:29.771 -- 00:00:34.992 Good morning and welcome to EMPLA Medical's conference call to review our second quarter 00:00:34.992 -- 00:00:40.754 2026 results. I'm Sveinn Solvason, President and CEO of EMPLA Medical. 00:00:40.754 -- 00:00:45.495 Joining me today are our Chief Financial Officer Anna Sveinsdottir and our Head of Investor 00:00:45.495 -- 00:00:47.675 Relations Klaus Sindahl. 00:00:47.675 -- 00:00:53.616 The presentation will take approximately 15 minutes followed by a Q&A session. 00:00:53.616 -- 00:00:57.357 If you please turn to the next slide. 00:00:58.323 -- 00:01:03.906 The first half of 2026 was strong. We delivered good organic growth, an increase in profitability, 00:01:03.906 -- 00:01:06.828 and solid free cash flow. 00:01:06.828 -- 00:01:11.930 Sales in the second quarter were $259 million, corresponding to 11% reported 00:01:11.930 -- 00:01:15.252 growth and 6% organic growth. 00:01:15.252 -- 00:01:19.574 Prosthetics and neuro-orthotics continued to do very well, with double-digit growth in 00:01:19.574 -- 00:01:24.737 the quarter. This was driven by strong execut...